A Phase 2 interventional study of Tofacitinib 2 mg and Tofacitinib 5 mg in Ankylosing Spondylitis, sponsored by Pfizer. Completed at 67 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-10.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 25th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 129 across the 18 interventional studies, 276 across the 16 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Spondylitis, Ankylosing by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Tofacitinib 2 mg
Drug: Tofacitinib 5 mg
Drug: Tofacitinib 10 mg
Drug: Placebo
4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12
The primary analysis of this outcome measure was performed using the Emax model. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of greater than or equal to (≥) 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and less than or equal to (≤)1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by nonresponsive (NRI)/ last observation carried forward (LOCF). Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
Time frame: Week 12
Percentage of Participants Achieving ASAS20 at Week 12
The supportive analysis of this outcome measure was performed using the normal approximation for two proportions. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
Time frame: Baseline, Week 12
Percentage of Participants Achieving 20% Improvement in ASAS Score at Weeks 2, 4 and 8
Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
Time frame: Baseline, Week 2, Week 4, Week 8
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12
SPARCC scoring consists of assessing six SI joint MRI image coronal slices representing the largest proportion of the synovial compartment of the SI joints for edema. The maximum score per slice was 2 and 12 for all 6 slices. The total minimum and maximum score for all SI joints across 6 slices is 0 to 72 and higher scores indicate more inflammation. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
Time frame: Baseline, Week 12
Change From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12
SPARCC scoring of the magnetic resonance imaging (MRI) of the spine consists of assessing six disco-vertebral units (DVU) with 3 consecutive sagittal slices at each DVU. The minimum and maximum SPARCC score for all 6 DVUs is 0 to 108, with higher scores indicating more damage. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
Time frame: Baseline, Week 12
Change From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12
Berlin modification of the ASspiMRI is a measure of acute lesion as determined by short-tau inversion recovery (STIR) sequences. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1), defined as the region between 2 virtual lines through the middle of each vertebra, were scored in a single dimension, which is represented the highest level of inflammation in that particular DVU. Total spine ASspiMRI scores can range from 0-69 with higher scores indicating more disease activity. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
Time frame: Baseline, Week 12
Percentage of Participants Achieving 40% Improvement in ASAS Score at Weeks 2, 4, 8 and 12
ASAS 40 is defined as ≥40% and absolute change of ≥2 units in at least 3 domains on a 0-10 scale (0=no disease activity, 10=high disease activity), and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Percentage of Participants Achieving ASAS5/6 Response at Weeks 2, 4, 8 and 12
ASAS5/6 consists of 6 domains: the 4 used in ASAS20 (Patient's Global Assessment of Disease Activity, spinal pain, function, inflammation plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). ASAS 5/6 is defined as ≥20% improvement in at least 5 domains and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline of Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein ASDAS(CRP) at Weeks 2, 4, 8 and 12
The ASDAS(CRP) is a derived score that uses back pain, duration of morning stiffness, Patient's Global Assessment of their disease and peripheral pain/swelling. The formula used for calculating the ASDAS (CRP)is: 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1). The calculated score can be from 0 to no defined upper limit. A negative number indicates a reduction in the score which indicates decrease in disease activity.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Percentage of Participants With ASDAS Clinically Important Improvement at Weeks 2, 4, 8 and 12
The ASDAS clinically important improvement was calculated from the ASDAS data. The ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units. Missing data were handled by NRI/LOCF.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Percentage of Participants With ASDAS Major Improvement at Weeks 2, 4, 8 and 12
The ASDAS major improvement was calculated from the ASDAS data. The ASDAS major improvement was defined as change (decrease) from baseline of ≥2.0 units. Missing data were handled by NRI/LOCF.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Percentage of Participants Achieving ASDAS Inactive Disease at Weeks 2, 4, 8 and 12
The ASDAS inactive disease was calculated from the ASDAS data. The ASDAS inactive disease was defined as ASDAS \<1.3 units. Missing data were handled by NRI/LOCF.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline in BASDAI Total Score at Week 2, 4, 8 and 12
BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. BASDAI=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The final BASDAI score averages the individual assessments for a final score range of 0-10. Negative values indicate improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Percentage of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 Response at Weeks 2, 4, 8 and 12
BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. The final BASDAI score range from 0-10. A positive response was defined as a 50% improvement in the BASDAI from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8 and 12
BASFI is a validated self-assessment tool that determines the degree of physical functional limitation in Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0=easy, 10=impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions with lower scores indicating better physical function. The higher the negative value the better the improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 2, 4, 8 and 12
BASMI is an objective measure of spinal mobility and was completed by a blinded assessor. The BASMI score is composed of 5 clinical measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. The derived score used the average of the 5 assessments on a scale of 0-10 scale with higher scores indicating more impairment of spinal mobility. BASMI was analyzed using the linear function method. The higher the negative value the better the improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8 and 12
Assessment of enthesitis of 13 sites was performed in the following, 1st costochondral joint left and right, 7th costochondral joint left and right, posterior superior iliac spine left and right, anterior superior iliac spine left and right, iliac crest left and right, 5th lumbar spinous process and proximal insertion of Achilles tendon left and right. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
Time frame: Baseline, Week 4, Week 8, Week 12
Extra-Articular Involvement From Specific Ankylosing Spondylitis Medical History
Participants were assessed at Baseline, Week 12 and Week 16 (Follow-up) to determine if they had specific Ankylosing Spondylitis medical history or changes in specific Ankylosing Spondylitis medical history which included: Inflammatory Bowel Disease (IBD), Peripheral Articular Involvement (PAI; as assessed by swollen joint count), psoriasis (PSO) and uveitis (UVE).
Time frame: Baseline, Week 12 and Follow-up
Change From Baseline of Total Swollen Joint Count at Weeks 2, 4 8 and 12
This assessment was performed by the blinded assessor using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints) for determination of the total number of swollen joints. Forty-four joints were assessed for swelling on left and right side and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (II, III, IV, V), knees, ankles, and metatarsophalangeals (I, II, III, IV, V). Artificial joints were not assessed. A negative change means improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline of Mean Spinal Mobility (Chest Expansion) at Week 2, 4, 8 and 12
Chest expansion, measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
Change From Baseline to Week 12 in Short-Form-36 Health Survey (SF-36) Physical and Mental Health Scores at Week 12
SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=no functioning, 100=highest level of functioning). Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
Time frame: Baseline, Week 12
Change From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 12
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of single utility score. Health state profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; Scale range 1 to 3 (1=better health state \[no problems\], 3=worst health state \[confined to bed\]).
Time frame: Baseline, Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 2, 4, 8 and 12
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12
| Milestone | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Started | 52 | 52 | 52 | 51 |
| Completed | 51 | 51 | 47 | 47 |
| Not completed | 1 | 1 | 5 | 4 |
| Withdrew: Adverse event | 0 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
The primary analysis of this outcome measure was performed using the Emax model. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of greater than or equal to (≥) 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and less than or equal to (≤)1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by nonresponsive (NRI)/ last observation carried forward (LOCF). Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12 | 56.0 | 63.0 | 67.4 | 40.1 |
The supportive analysis of this outcome measure was performed using the normal approximation for two proportions. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Percentage of Participants Achieving ASAS20 at Week 12 | 51.92 | 80.77 | 55.77 | 41.18 |
Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=21,17,18,14) | 40.38 | 32.69 | 34.62 | 27.45 |
| Week 4 (n=25,29,25,17) | 48.08 | 55.77 | 48.08 | 33.33 |
| Week 8 (n=30, 37, 28, 22) | 57.69 | 71.15 | 53.85 | 43.14 |
SPARCC scoring consists of assessing six SI joint MRI image coronal slices representing the largest proportion of the synovial compartment of the SI joints for edema. The maximum score per slice was 2 and 12 for all 6 slices. The total minimum and maximum score for all SI joints across 6 slices is 0 to 72 and higher scores indicate more inflammation. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12 | -1.70 ± 0.779 | -3.15 ± 0.788 | -3.55 ± 0.795 | -0.81 ± 0.806 |
SPARCC scoring of the magnetic resonance imaging (MRI) of the spine consists of assessing six disco-vertebral units (DVU) with 3 consecutive sagittal slices at each DVU. The minimum and maximum SPARCC score for all 6 DVUs is 0 to 108, with higher scores indicating more damage. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Change From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12 | -3.09 ± 1.061 | -5.51 ± 1.063 | -6.57 ± 1.073 | -0.09 ± 1.085 |
Berlin modification of the ASspiMRI is a measure of acute lesion as determined by short-tau inversion recovery (STIR) sequences. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1), defined as the region between 2 virtual lines through the middle of each vertebra, were scored in a single dimension, which is represented the highest level of inflammation in that particular DVU. Total spine ASspiMRI scores can range from 0-69 with higher scores indicating more disease activity. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Change From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12 | -1.05 ± 0.364 | -2.22 ± 0.364 | -2.13 ± 0.368 | -0.41 ± 0.372 |
ASAS 40 is defined as ≥40% and absolute change of ≥2 units in at least 3 domains on a 0-10 scale (0=no disease activity, 10=high disease activity), and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=7, 7, 9, 8) | 13.46 | 13.46 | 17.31 | 15.69 |
| Week 4 (n=15, 17, 11, 8) | 28.85 | 32.69 | 21.15 | 15.69 |
| Week 8 (n=15, 18, 19, 14) | 28.85 | 34.62 | 36.54 | 27.45 |
| Week 12 (n=22, 24, 20, 10) | 42.31 | 46.15 | 38.46 | 19.61 |
ASAS5/6 consists of 6 domains: the 4 used in ASAS20 (Patient's Global Assessment of Disease Activity, spinal pain, function, inflammation plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). ASAS 5/6 is defined as ≥20% improvement in at least 5 domains and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=12, 7, 11, 4) | 23.08 | 13.46 | 21.15 | 7.84 |
| Week 4 (n=10, 16, 15, 4) | 19.23 | 30.77 | 28.85 | 7.84 |
| Week 8 (n=11, 22, 15, 5) | 21.15 | 42.31 | 28.85 | 9.80 |
| Week 12 (n=10, 26, 20, 8) | 19.23 | 50.00 | 38.46 | 15.69 |
The ASDAS(CRP) is a derived score that uses back pain, duration of morning stiffness, Patient's Global Assessment of their disease and peripheral pain/swelling. The formula used for calculating the ASDAS (CRP)is: 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1). The calculated score can be from 0 to no defined upper limit. A negative number indicates a reduction in the score which indicates decrease in disease activity.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | -0.68 ± 0.096 | -1.00 ± 0.096 | -0.97 ± 0.096 | -0.50 ± 0.097 |
| Week 4 | -1.01 ± 0.099 | -1.20 ± 0.099 | -1.17 ± 0.099 | -0.58 ± 0.100 |
| Week 8 | -1.08 ± 0.111 | -1.36 ± 0.111 | -1.32 ± 0.112 | -0.73 ± 0.112 |
| Week 12 | -1.23 ± 0.119 | -1.41 ± 0.119 | -1.37 ± 0.121 | -0.68 ± 0.123 |
The ASDAS clinically important improvement was calculated from the ASDAS data. The ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units. Missing data were handled by NRI/LOCF.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=14, 25, 21, 8) | 26.92 | 48.08 | 40.38 | 15.69 |
| Week4 (n=22, 30, 27, 10) | 42.31 | 57.69 | 51.92 | 19.61 |
| Week 8 (n=23, 31, 31, 15) | 44.23 | 59.62 | 59.62 | 29.41 |
| Week 12 (n=27, 33, 29, 14) | 51.92 | 63.46 | 55.77 | 27.45 |
The ASDAS major improvement was calculated from the ASDAS data. The ASDAS major improvement was defined as change (decrease) from baseline of ≥2.0 units. Missing data were handled by NRI/LOCF.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=4, 4, 4, 1) | 7.69 | 7.69 | 7.69 | 1.96 |
| Week 4 (n=6, 6, 8, 3) | 11.54 | 11.54 | 15.38 | 5.88 |
| Week 8 (n=6, 14, 12, 5) | 11.54 | 26.92 | 23.08 | 9.80 |
| Week 12 (n=10, 12, 13, 6) | 19.23 | 23.08 | 25.00 | 11.76 |
The ASDAS inactive disease was calculated from the ASDAS data. The ASDAS inactive disease was defined as ASDAS \<1.3 units. Missing data were handled by NRI/LOCF.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=1, 1, 1, 0) | 1.92 | 1.92 | 1.92 | 0.00 |
| Week 4 (n=1, 3, 4, 1) | 1.92 | 5.77 | 7.69 | 1.96 |
| Week 8 (n=3, 1, 5, 1) | 5.77 | 1.92 | 9.62 | 1.96 |
| Week 12 (n=7, 7, 8, 4) | 13.46 | 13.46 | 15.38 | 7.84 |
BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. BASDAI=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The final BASDAI score averages the individual assessments for a final score range of 0-10. Negative values indicate improvement.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | -1.45 ± 0.219 | -1.53 ± 0.217 | -1.24 ± 0.219 | -1.42 ± 0.219 |
| Week 4 | -1.90 ± 0.242 | -1.93 ± 0.240 | -1.84 ± 0.242 | -1.60 ± 0.243 |
| Week 8 | -2.16 ± 0.268 | -2.39 ± 0.267 | -2.35 ± 0.271 | -1.87 ± 0.271 |
| Week 12 | -2.75 ± 0.277 | -2.88 ± 0.276 | -2.68 ± 0.281 | -1.85 ± 0.283 |
BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. The final BASDAI score range from 0-10. A positive response was defined as a 50% improvement in the BASDAI from baseline.
| Percentage of participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 (n=6, 11, 7, 8) | 11.54 (2.92 to 20.61) | 21.15 | 13.46 | 15.69 |
| Week 4 (n=15, 12, 15, 11) | 28.85 | 23.08 | 28.85 | 21.57 |
| Week 8 (n=18, 17, 21, 14) | 34.62 | 32.69 | 40.38 | 27.45 |
| Week 12 (n=24, 22, 22, 12) | 46.15 | 42.31 | 42.31 | 23.53 |
BASFI is a validated self-assessment tool that determines the degree of physical functional limitation in Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0=easy, 10=impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions with lower scores indicating better physical function. The higher the negative value the better the improvement.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | -1.12 ± 0.192 | -1.16 ± 0.191 | -0.86 ± 0.192 | -0.74 ± 0.192 |
| Week 4 | -1.36 ± 0.210 | -1.61 ± 0.208 | -1.32 ± 0.210 | -1.02 ± 0.210 |
| Week 8 | -1.61 ± 0.247 | -2.07 ± 0.246 | -1.72 ± 0.249 | -1.38 ± 0.249 |
| Week 12 | -1.90 ± 0.261 | -2.39 ± 0.260 | -2.24 ± 0.264 | -1.43 ± 0.266 |
BASMI is an objective measure of spinal mobility and was completed by a blinded assessor. The BASMI score is composed of 5 clinical measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. The derived score used the average of the 5 assessments on a scale of 0-10 scale with higher scores indicating more impairment of spinal mobility. BASMI was analyzed using the linear function method. The higher the negative value the better the improvement.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | -0.09 ± 0.075 | -0.24 ± 0.075 | -0.22 ± 0.075 | -0.09 ± 0.075 |
| Week 4 | -0.15 ± 0.083 | -0.24 ± 0.083 | -0.26 ± 0.084 | -0.14 ± 0.084 |
| Week 8 | -0.34 ± 0.095 | -0.40 ± 0.095 | -0.48 ± 0.096 | -0.19 ± 0.096 |
| Week 12 | -0.33 ± 0.109 | -0.42 ± 0.109 | -0.55 ± 0.111 | -0.16 ± 0.112 |
Assessment of enthesitis of 13 sites was performed in the following, 1st costochondral joint left and right, 7th costochondral joint left and right, posterior superior iliac spine left and right, anterior superior iliac spine left and right, iliac crest left and right, 5th lumbar spinous process and proximal insertion of Achilles tendon left and right. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 4 | -0.16 ± 0.272 | -0.93 ± 0.271 | -0.89 ± 0.274 | -0.11 ± 0.275 |
| Week 8 | -0.79 ± 0.289 | -1.19 ± 0.289 | -0.97 ± 0.295 | -0.54 ± 0.292 |
| Week 12 | -0.66 ± 0.259 | -1.37 ± 0.259 | -1.24 ± 0.263 | -0.34 ± 0.265 |
Participants were assessed at Baseline, Week 12 and Week 16 (Follow-up) to determine if they had specific Ankylosing Spondylitis medical history or changes in specific Ankylosing Spondylitis medical history which included: Inflammatory Bowel Disease (IBD), Peripheral Articular Involvement (PAI; as assessed by swollen joint count), psoriasis (PSO) and uveitis (UVE).
| Percentage of Participants | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| IBD: Never: Baseline (n=6, 9, 6, 4) | 100 | 88.9 | 100 | 100 |
| IBD: Past But Not Active: Baseline (n=6, 9, 6, 4) | 0 | 0 | 0 | 0 |
| IBD: Currently Active: Baseline (n=6, 9, 6, 4) | 0 | 11.1 | 0 | 0 |
| IBD: New Condition: Baseline (n=6, 9, 6, 4) | 0 | 0 | 0 | 0 |
| IBD: Never: Week 4 (n=4, 7, 3, 2) | 100 | 100 | 100 | 100 |
| IBD: Past But Not Active: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| IBD: Currently Active: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| IBD: New Condition: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| IBD: Never: Week 8 (n=2, 6, 2, 4) | 100 | 100 | 100 | 100 |
| IBD: Past But Not Active: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| IBD: Currently Active: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| IBD: New Condition: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| IBD: Never: Week 12 (n=5, 6, 2, 3) | 100 | 100 | 100 | 100 |
| IBD: Past But Not Active: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| IBD: Currently Active: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| IBD: New Condition: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| IBD: Never: Follow-up (n=3, 6, 4, 2) | 100 | 100 | 100 | 100 |
| IBD: Past But Not Active: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 0 | 0 |
| IBD: Currently Active: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 0 | 0 |
| IBD: New Condition: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 0 | 0 |
| PAI: Never: Baseline (n=6, 9, 6, 4) | 33.3 | 44.4 | 0 | 25.0 |
| PAI: Past But Not Active: Baseline (n=6, 9, 6, 4) | 0 | 0 | 16.7 | 0 |
| PAI: Currently Active: Baseline (n=6, 9, 6, 4) | 66.7 | 44.4 | 66.7 | 75.0 |
| PAI: New condition: Baseline (n=6, 9, 6, 4) | 0 | 11.1 | 16.7 | 0 |
| PAI: Never: Week 4 (n=4, 7, 3, 2) | 0 | 28.6 | 0 | 0 |
| PAI: Past But Not Active: Week 4 (n=4, 7, 3, 2) | 0 | 14.3 | 33.3 | 0 |
| PAI: Currently Active: Week 4 (n=4, 7, 3, 2) | 100 | 57.1 | 66.7 | 100 |
| PAI: New condition: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| PAI: Never: Week 8 (n=2, 6, 2, 4) | 0 | 50.0 | 0 | 0 |
| PAI: Past But Not Active: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 50.0 | 0 |
| PAI: Currently Active: Week 8 (n=2, 6, 2, 4) | 100 | 50.0 | 50.0 | 100 |
| PAI: New Condition: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| PAI: Never: Week 12 (n=5, 5, 2, 3) | 20.0 | 40.0 | 0 | 0 |
| PAI: Past But Not Active: Week 12 (n=5, 5, 2, 3) | 0 | 0 | 0 | 0 |
| PAI: Currently Active: Week 12 (n=5, 5, 2, 3) | 40.0 | 60.0 | 100 | 100 |
| PAI: New Condition: Week 12 (n=5, 5, 2, 3) | 40.0 | 0 | 0 | 0 |
| PAI: Never: Follow-up (n=3, 6, 4, 2) | 0 | 50.0 | 25.0 | 0 |
| PAI: Past But Not Active: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 25.0 | 0 |
| PAI: Currently Active: Follow-up (n=3, 6, 4, 2) | 66.7 | 50.0 | 50.0 | 100 |
| PAI: New Condition: Follow-up (n=3, 6, 4, 2) | 33.3 | 0 | 0 | 0 |
| PSO: Never: Baseline (n=6, 9, 6, 4) | 100 | 88.9 | 83.3 | 75.0 |
| PSO: Past But Not Active: Baseline (n=6, 9, 6, 4) | 0 | 0 | 0 | 0 |
| PSO: Currently Active: Baseline (n=6, 9, 6, 4) | 0 | 11.1 | 16.7 | 25.0 |
| PSO: New Condition: Baseline (n=6, 9, 6, 4) | 0 | 0 | 0 | 0 |
| PSO: Never: Week 4 (n=4, 7, 3, 2) | 100 | 85.7 | 66.7 | 100 |
| PSO: Past But Not Active: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| PSO: Currently Active: Week 4 (n=4, 7, 3, 2) | 0 | 14.3 | 33.3 | 0 |
| PSO: New Condition: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| PSO: Never: Week 8 (n=2, 6, 2, 4) | 100 | 83.3 | 50.0 | 100 |
| PSO: Past But Not Active: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| PSO: Currently Active: Week 8 (n=2, 6, 2, 4) | 0 | 16.7 | 50.0 | 0 |
| PSO: New Condition: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| PSO: Never: Week 12 (n=5, 6, 2, 3) | 80.0 | 83.3 | 100 | 100 |
| PSO: Past But Not Active: Week 12 (n=5, 6, 2, 3) | 20.0 | 0 | 0 | 0 |
| PSO: Currently Active: Week 12 (n=5, 6, 2, 3) | 0 | 16.7 | 0 | 0 |
| PSO: New Condition: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| PSO: Never: Follow-up (n=3, 6, 4, 2) | 100 | 83.3 | 100 | 100 |
| PSO: Past But Not Active: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 0 | 0 |
| PSO: Currently Active: Follow-up (n=3, 6, 4, 2) | 0 | 16.7 | 0 | 0 |
| PSO: New Condition: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 0 | 0 |
| UVE: Never: Baseline (n=6, 9, 6, 4) | 50.0 | 55.6 | 83.3 | 100 |
| UVE: Past But Not Active: Baseline (n=6, 9, 6, 4) | 16.7 | 33.3 | 0 | 0 |
| UVE: Currently Active: Baseline (n=6, 9, 6, 4) | 33.3 | 11.1 | 16.7 | 0 |
| UVE: New Condition: Baseline (n=6, 9, 6, 4) | 0 | 0 | 0 | 0 |
| UVE: Never: Week 4 (n=4, 7, 3, 2) | 75.0 | 71.4 | 66.7 | 100 |
| UVE: Past But Not Active: Week 4 (n=4, 7, 3, 2) | 25.0 | 28.6 | 33.3 | 0 |
| UVE: Currently Active: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| UVE: New Condition: Week 4 (n=4, 7, 3, 2) | 0 | 0 | 0 | 0 |
| UVE: Never: Week 8 (n=2, 6, 2, 4) | 100 | 50.0 | 50.0 | 100 |
| UVE: Past But Not Active: Week 8 (n=2, 6, 2, 4) | 0 | 50.0 | 50.0 | 0 |
| UVE: Currenly Active: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| UVE: New Condition: Week 8 (n=2, 6, 2, 4) | 0 | 0 | 0 | 0 |
| UVE: Never: Week 12 (n=5, 6, 2, 3) | 40.0 | 66.7 | 50.0 | 100 |
| UVE: Past But Not Active: Week 12 (n=5, 6, 2, 3) | 60.0 | 33.3 | 50.0 | 0 |
| UVE: Currently Active: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| UVE: New Condition: Week 12 (n=5, 6, 2, 3) | 0 | 0 | 0 | 0 |
| UVE: Never: Follow-up (n=3, 6, 4, 2) | 100 | 50.0 | 50.0 | 100 |
| UVE: Past But Not Active: Follow-up (n=3, 6, 4, 2) | 0 | 33.3 | 25.0 | 0 |
| UVE: Currently Active: Follow-up (n=3, 6, 4, 2) | 0 | 16.7 | 0 | 0 |
| UVE: New Condition: Follow-up (n=3, 6, 4, 2) | 0 | 0 | 25.0 | 0 |
This assessment was performed by the blinded assessor using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints) for determination of the total number of swollen joints. Forty-four joints were assessed for swelling on left and right side and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (II, III, IV, V), knees, ankles, and metatarsophalangeals (I, II, III, IV, V). Artificial joints were not assessed. A negative change means improvement.
| Swollen Joints | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | -0.53 ± 0.293 | 0.23 ± 0.291 | -1.20 ± 0.292 | -0.43 ± 0.293 |
| Week 4 | -0.87 ± 0.260 | -0.57 ± 0.259 | -1.23 ± 0.260 | -0.86 ± 0.261 |
| Week 8 | -1.02 ± 0.442 | -0.98 ± 0.442 | -1.28 ± 0.451 | -0.60 ± 0.448 |
| Week 12 | -0.87 ± 0.362 | -0.79 ± 0.362 | -1.40 ± 0.368 | -0.99 ± 0.373 |
Chest expansion, measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
| cm | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | 0.30 ± 0.144 | 0.35 ± 0.143 | -0.03 ± 0.144 | 0.24 ± 0.144 |
| Week 4 | 0.54 ± 0.164 | 0.13 ± 0.162 | 0.13 ± 0.164 | 0.38 ± 0.165 |
| Week 8 | 0.52 ± 0.178 | 0.35 ± 0.178 | 0.15 ± 0.182 | 0.13 ± 0.181 |
| Week 12 | 0.69 ± 0.187 | 0.49 ± 0.187 | 0.13 ± 0.190 | 0.31 ± 0.193 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=no functioning, 100=highest level of functioning). Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 12 Physical Health Score | 6.34 ± 0.923 | 6.49 ± 0.914 | 7.05 ± 0.943 | 2.69 ± 0.932 |
| Week 12 Mental Health Score | 2.08 ± 1.306 | 4.15 ± 1.294 | 3.71 ± 1.336 | 2.41 ± 1.318 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of single utility score. Health state profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; Scale range 1 to 3 (1=better health state \[no problems\], 3=worst health state \[confined to bed\]).
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Change From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 12 | 0.17 ± 0.034 | 0.16 ± 0.034 | 0.22 ± 0.035 | 0.10 ± 0.034 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
| Units on a scale | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Week 2 | 3.62 ± 0.871 | 1.97 ± 0.871 | 2.17 ± 0.875 | 1.90 ± 0.872 |
| Week 4 | 4.25 ± 0.931 | 3.67 ± 0.927 | 2.80 ± 0.937 | 2.71 ± 0.938 |
| Week 8 | 4.54 ± 1.039 | 4.81 ± 1.039 | 4.19 ± 1.061 | 2.85 ± 1.053 |
| Week 12 | 4.74 ± 1.145 | 7.03 ± 1.145 | 7.58 ± 1.166 | 3.08 ± 1.178 |
Collected over From informed consent through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 2 mg BID | — | 0/52 (0%) | 15/52 (28.8%) |
| Tofacitinib 5 mg BID | — | 1/52 (1.9%) | 10/52 (19.2%) |
| Tofacitinib 10 mg BID | — | 1/52 (1.9%) | 13/52 (25%) |
| Placebo BID | — | 2/51 (3.9%) | 14/51 (27.5%) |
| Event | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| Foetal deathPregnancy, puerperium and perinatal conditions | 0/18 | 0/13 | 0/14 | 1/19 |
| Uterine spasmReproductive system and breast disorders | 0/18 | 0/13 | 0/14 | 1/19 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/18 | 0/13 | 0/14 | 1/19 |
| VertigoEar and labyrinth disorders | 0/52 | 0/52 | 0/52 | 1/51 |
| IridocyclitisEye disorders | 0/52 | 1/52 | 0/52 | 0/51 |
| Tendon injuryInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/52 | 0/51 |
| Event | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/52 | 4/52 | 2/52 | 3/51 |
| Upper respiratory tract infectionInfections and infestations | 4/52 | 0/52 | 3/52 | 1/51 |
| Abdominal pain upperGastrointestinal disorders | 3/52 | 0/52 | 2/52 | 1/51 |
| Vulvovaginal mycotic infectionInfections and infestations | 1/18 | 0/13 | 0/14 | 0/19 |
| Vaginitis bacterialInfections and infestations | 0/18 | 0/13 | 0/14 | 1/19 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/18 | 0/13 | 0/14 | 1/19 |
| BronchitisInfections and infestations | 0/52 | 0/52 | 1/52 | 2/51 |
| DizzinessNervous system disorders | 0/52 | 0/52 | 0/52 | 2/51 |
| RashSkin and subcutaneous tissue disorders | 1/52 | 0/52 | 0/52 | 2/51 |
| DiarrhoeaGastrointestinal disorders | 2/52 | 1/52 | 0/52 | 1/51 |
Safety population - included participants who received at least 1 dose of study medication
| Age, Continuous(Years) | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID | Total |
|---|---|---|---|---|---|
| Age | 41.8 ± 12.3 | 41.2 ± 10.3 | 41.6 ± 12.2 | 41.9 ± 12.9 | 41.6 ± 11.9 |
| Sex: Female, Male(Participants) | Tofacitinib 2 mg BID | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Placebo BID | Total |
|---|---|---|---|---|---|
| Female | 18 | 13 | 14 | 19 | 64 |
| Male | 34 | 39 | 38 | 32 | 143 |
The record gives a start of Apr 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib